In this MedPage Today video, Taylor Brooks, MD, of the Cleveland Clinic Cancer Institute, discusses real-world survival ...

Since 2015, Dana-Farber researchers have been participating in clinical trials that evaluate the use of bispecific antibodies for patients with non-Hodgkin lymphoma. Three bispecific antibody ...

At the recent American Society of Hematology (ASH) annual meeting, phase II data were presented on a bispecific antibody for ...

DUBLIN--(BUSINESS WIRE)--The "Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029" report has been added to ResearchAndMarkets.com ...

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an update. Shanghai Henlius Biotech has initiated a first-in-human phase 1 ...

Genmab is discontinuing development of acasunlimab after a pipeline review, pivoting focus to other oncology antibodies.

Panelists discuss how recent FDA approvals for bispecific antibodies in oncology, particularly for hematologic malignancies like multiple myeloma and lymphomas, represent significant treatment ...

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

Shaji Kumar, MD, Mayo Clinic, highlights linvoseltamab’s dosing regimen, adverse effect profile, and management strategies. He speaks in particular about cytokine release syndrome, which although ...

Ever since the first bispecific antibody received regulatory approval in 2009, increasingly sophisticated bispecific antibodies have been sought, particularly in cancer research. Bispecific antibodies ...

Bispecific antibodies (bispecifics) can simultaneously target two distinct antigens or epitopes, offering novel therapeutic strategies such as enhancing immune cell targeting of cancer cells or ...